Weinblat, M.Baranauskaite, A.Niebrzydowski, J.Dokoupilova, E.Zielinska, A.Sitek-Ziolkowska, K.Jaworski, J.Racewicz, A.Pileckyte, M.Jedrychowicz-Rosiak, K.Zhdan, V.Cheong, SY.Ghil, J.Ждан, Вячеслав Миколайович2018-09-252018-09-252016-11-13Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study[Електронний ресурс] /M. Weinblatt, A. Baranauskaite, J. Niebrzydowski [at al.] // American College of Rheumatology. November 13, 2016. Режим доступу до журн.: https://acrabstracts.org/abstract/sustained-efficacy-and-comparable-safety-and-immunogenicity-after-transition-to-sb5-an-adalimumab-biosimilar-vs-continuation-of-sb5-or-reference-adalimumab-humira-in-patients-with-rheumatoihttps://repository.pdmu.edu.ua/handle/123456789/8673enbiosimilarsArticle